Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (837)	3/13/2001 11:27:45 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120405

this is a little biotech to just tuck away on a list and watch for a while: (COMTEX) B: PROTIDE PHARMACEUTICALS, INC. - Signs Option Agreement Wi B: PROTIDE PHARMACEUTICALS, INC. - Signs Option Agreement With the University of Minnesota New York, New York, Mar 13, 2001 (Market News Publishing via COMTEX) -- Protide Pharmaceuticals, Inc. (Protide), announced it has signed an option agreement with the University of Minnesota Office of Patents and Technology Marketing for an infusible grade solution for non-cryopreserved human hematopoietic stem cells. The technology provides short-term liquid storage for cells transported from collection centers to transplantation and cell processing centers. The interval between cell collection and transplantation or processing may be as long as one or two days. This option agreement will allow Protide to have the exclusive right to evaluate the technology and possibly commence negotiations with the University for worldwide commercialization. "This technology may be an important addition to our clinical cell therapy program" said Milo R. Polovina, Chairman & CEO. Protide has developed technologies for cryopreservation, transfusion and ex vivo expansion of human cells as part of its cell therapy platform. The Company has filed with the Food and Drug Administration (FDA) to initiate phase I clinical trials for its lead product ViaStem(TM). The FDA has placed this trial on clinical hold pending further information. ViaStem(TM) was developed to improve the storage and transfusion of stem cells from bone marrow, peripheral blood and umbilical cord blood while a patient receives intensive chemotherapy or radiation treatment for certain cancers, blood disorders and serious genetic disorders. Protide Pharmaceuticals, Inc. is a biotechnology company devoted to the discovery, development and commercialization of technologies and processes in clinical cell therapy, transplant and transfusion medicine, specifically in the areas of cancer, genetic disorders and cell engineering. Additional information can be found at www.protidepharma.com and www.celox.com. The statements made in this press release may contain certain forward-looking statements that involve a number of risks and uncertainties. Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Protide cautions investors and others that any forward-looking statements or projections made by the company, including those made in this press release, are subject to risks and uncertainties that may cause actual results to differ from those projected. In addition, the risk factors listed from time to time in the company's SEC filings, including but not limited to its Annual Report on Form 10-KSB for the year ended August 31, 2000, may affect actual results achieved by the company. CONTACT: TEL: 651/730-1500 Protide Pharmaceuticals, Inc., St. Paul Milo R. Polovina, David E. Tess MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041. (C) 2001 Market News Publishing Inc. -0- KEYWORD: New York, New York * end of story *